FDG-PET on the trail of an unsuspected primary malignancy in the breast

Clinical Nuclear Medicine

Volumn 33, Issue 3, 2008, Pages 175-180

  Dockery, Keith F ^a,b   Puri, Savita ^a   Qazi, Raman ^a   Davis, Delphine ^a  

^a Highland Hospital Rochester   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Breast cancer; F 18 fluorodeoxyglucose; FDG PET; Unknown primary tumor of origin

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE;

ADENOCARCINOMA; ADULT; ARTICLE; BREAST BIOPSY; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DISTRIBUTION; DRUG METABOLISM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHADENOPATHY; LYMPHEDEMA; POSITRON EMISSION TOMOGRAPHY; TREATMENT RESPONSE;

ADENOCARCINOMA; BIOPSY; BREAST NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 39749121435     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e318162ddee     Document Type: Article

References (8)

1. Som P, Alkins HL, Bandoypadhayay D, et al. A fluorinated glucose analog. 2 Fluoro-2deoxy-2-d glucose [18F]: nontoxic tracer for rapid tumor detection. J Nucl Med. 1980;21:670-675.
2. Delbeke D. Oncological applications of FDG-PET imaging. J Nucl Med. 1999;40:1706-1715.
3. Gambhir SS, Czeynin J, Schwimmer J, et al. A tabulated summary of the literature. J Nucl Med. 2001;42(suppl 1):1-935.
4. Gudzeit A, Antoch G, Kuhl H, et al. Unknown primary tumors: detection with dual modality PET/CT-initial experience. Radiology. 2005;234:227-234.
5. Avril N, Rose CA, Schelling M, et al. Breast imaging with positron emission tomography and F-18 fluorodeoxyglucose: use and limitations. J Clin Oncol. 2000;18:3495-3502.
6. Schoder H, Young HWD, Gonen M, et al. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology. 2004;231:65-72.
7. Crippa F, Seregni E, Agresti R, et al. Association between [18F] fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labeling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med. 1998;25:1429-1434.
8. Eubank WB, Mankoft DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med. 2005;35:84-99.